Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations (Q37918556)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 August 2011

Language	Label	Description	Also known as
English	Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations	scientific article published on 17 August 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

1 reference

ChEBI release 2020-05-28

invasive fungal infections

1 reference

based on heuristic

inferred from title

3

object named as

John R Perfect

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

author name string

Stuart K Pitman

1

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Richard H Drew

2

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

language of work or name

0 references

publication date

17 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

number of pages

28

1 reference

based on heuristic

inferred from page(s)

Expert Opinion on Emerging Drugs

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

559-586

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Attributable mortality of nosocomial candidemia, revisited

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

The economic costs to United States hospitals of invasive fungal infections in transplant patients

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Epidemiology of invasive mycoses in North America

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Omeprazole significantly reduces posaconazole serum trough level

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Voriconazole: a new triazole antifungal agent

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Antifungal agents--clinical pharmacokinetics and drug interactions

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Complexity of interactions between voriconazole and antiretroviral agents

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Persistent photopsia following course of oral voriconazole

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Hallucinations during voriconazole therapy

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Overview of antifungal agents

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Antifungal use in hospitalized adults in U.S. academic health centers

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Use of Antifungal Combination Therapy: Agents, Order, and Timing

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Editorial commentary: what is the role of combination therapy in management of zygomycosis?

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Echinocandin pharmacodynamics: review and clinical implications.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Overview of the lipid formulations of amphotericin B.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in pat

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Randomized, Comparative, Double-Blind, Double-Dummy, Multicenter Trial of Miconazole Buccal Tablet and Clotrimazole Troches for the Treatment of Oropharyngeal Candidiasis: Study of Miconazole Lauriad®Efficacy and Safety (SMiLES)

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Amphotericin B formulations and drug targeting

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Development and evaluation of novel itraconazole-loaded intravenous nanoparticles

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

New and emerging treatments for fungal infections

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

New generation azole antifungals in clinical investigation

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activities of four novel triazoles against Scedosporium spp

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro antifungal susceptibility of Cryptococcus gattii

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Activities of available and investigational antifungal agents against rhodotorula species

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of albaconazole against Candida albicans in a vaginitis model

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro and in vivo activities of the novel azole antifungal agent r126638.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/corporis: two exploratory phase IIa trials

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of a single oral dose of 200 mg pramiconazole in vulvovaginal yeast infections: an exploratory phase IIa trial

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

The role of iron and iron chelators in zygomycosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Deferiprone iron chelation as a novel therapy for experimental mucormycosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

An insight into the antifungal pipeline: selected new molecules and beyond.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Comparison of susceptibility of fungal isolates to lufenuron and nikkomycin Z alone or in combination with itraconazole

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of micafungin alone or in combination against systemic murine aspergillosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Pharmacokinetics of nikkomycin Z after single rising oral doses

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Anticandidal activity of SPA-S-843, a new polyenic drug

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of SPK-843, a novel polyene antifungal, in a murine model of systemic cryptococcosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efungumab and caspofungin: pre-clinical data supporting synergy

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-Hodgkin lymphoma using Efungumab and amphotericin B colloid dispersion

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Treatment of a critically ill child with disseminated Candida glabrata with a recombinant human antibody specific for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin, and voriconazole.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Heat shock protein inhibitors for the treatment of fungal infections

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Fungal vaccines: real progress from real challenges

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Polysaccharide-containing conjugate vaccines for fungal diseases.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Pharmacological indices in antibiotic therapy

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro and in vivo antifungal activities of T-2307, a novel arylamidine

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

FR290581, a novel sordarin derivative: synthesis and antifungal activity

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Determination of MICs of aminocandin for Candida spp. and filamentous fungi

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

The novel antifungal agent PLD-118 is neither metabolized by liver microsomes nor inhibits cytochrome P450 in vitro.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Current options in antifungal pharmacotherapy.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Chitin synthesis as target for antifungal drugs

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Beta-glucan-CRM197 conjugates as candidates antifungal vaccines

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

A novel glyco-conjugate vaccine against fungal pathogens

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Developing a vaccine against aspergillosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Saccharomyces cerevisiae as a vaccine against coccidioidomycosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Prevalence and Treatment Management of Oropharyngeal Candidiasis in Cancer Patients: Results of the French Candidoscope Study

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Pharmacology of Systemic Antifungal Agents

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.607811

21 January 2018

Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation

1 reference

27 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1086/506617

Identifiers

10.1517/14728214.2011.607811

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37918556&oldid=1765958445"